Medexus Pharmaceuticals Inc. (MEDXF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medexus Pharmaceuticals Inc. (MEDXF) trades at $3.61 with AI Score 47/100 (Grade C). Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on oncology, hematology, rheumatology, auto-immune diseases, and allergy. Market cap: $114M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for MEDXF: MEDXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MEDXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MEDXF: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Medexus Pharmaceuticals Inc. (MEDXF) Healthcare & Pipeline Overview
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company operating in the US and Canada, focusing on niche therapeutic areas like oncology and rheumatology. With key products such as Rasuvo and IXINITY, Medexus navigates a competitive landscape, balancing growth opportunities with the inherent risks of the pharmaceutical industry, including regulatory hurdles and market access challenges.
What Is the Investment Thesis for MEDXF?
Medexus Pharmaceuticals Inc. presents a mixed investment case. The company's focus on specialty pharmaceuticals in niche therapeutic areas like rheumatology and hematology offers potential for targeted growth. Key to the investment thesis is the successful commercialization and market penetration of its core products, including Rasuvo, Metoject, and IXINITY. However, the company's negative profit margin of -0.2% and a high P/E ratio of -308.88 raise concerns about profitability and valuation. Growth catalysts include expanding market share within existing therapeutic areas and potential acquisitions of complementary products. Investors should closely monitor the company's ability to improve its financial performance and manage its debt levels. The high beta of 1.87 indicates significant volatility, making this a higher-risk investment.
Based on FMP financials and quantitative analysis
MEDXF Key Highlights
Market Cap of $114M indicates a small-cap company with potential for growth but also higher risk.
- P/E Ratio of -308.88 reflects current unprofitability, requiring careful analysis of future earnings potential.
- Gross Margin of 53.9% suggests strong pricing power on existing products, but needs to translate to overall profitability.
- Beta of 1.87 indicates higher volatility compared to the market, appealing to risk-tolerant investors.
- Focus on specialty therapeutic areas like oncology and rheumatology offers targeted growth opportunities.
Who Are MEDXF's Competitors?
MEDXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DBCCF Decibel Cannabis Company Inc. | $0.09 | +3.41% | $51.3M | 45 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| INIS Radnostix, Inc. | $0.06 | +14.29% | $33.9M | 48 |
| MILFF 1CM Inc. | $0.10 | +0.00% | $11.7M | 48 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MEDXF's Key Strengths?
Specialized product portfolio targeting niche therapeutic areas.
- Established presence in Canada and the United States.
- Proprietary formulations and intellectual property.
- Experienced management team with expertise in specialty pharmaceuticals.
What Are MEDXF's Weaknesses?
Small market capitalization and limited financial resources.
- Negative profit margin and high P/E ratio.
- Reliance on a limited number of products.
- High beta indicating significant volatility.
What Could Drive MEDXF Stock Higher?
Expansion of sales and marketing efforts for existing products.
- Potential acquisitions of complementary products or companies.
- Regulatory approvals for new formulations or indications.
- Strategic partnerships and licensing agreements.
- Geographic expansion into new markets.
What Are the Key Risks for MEDXF?
Financial-distress signal — its Altman Z-Score of 1.32 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-4.6%) — the business is not currently generating profit on shareholder capital.
- Competition from larger pharmaceutical companies.
- Pricing pressures and healthcare reforms.
- Patent expirations and generic competition.
- Regulatory risks and delays in product approvals.
- Limited financial resources and profitability concerns.
What Are the Growth Opportunities for MEDXF?
- Expanding Market Share of Existing Products: Medexus can focus on increasing the market penetration of its existing products, such as Rasuvo and Metoject, within their respective therapeutic areas. This involves targeted marketing campaigns, expanding the sales force, and securing favorable reimbursement policies from payers. The market for rheumatoid arthritis and other auto-immune diseases is substantial, offering significant growth potential. Timeline: Ongoing.
- Acquisition of Complementary Products: Medexus can pursue strategic acquisitions of complementary products or companies to expand its portfolio and geographic reach. This can provide access to new therapeutic areas, technologies, or markets, diversifying the company's revenue streams and reducing its reliance on a limited number of products. The specialty pharmaceutical market is fragmented, offering numerous acquisition opportunities. Timeline: Ongoing.
- Geographic Expansion: Medexus can expand its geographic presence beyond Canada and the United States, targeting new markets with unmet medical needs. This involves establishing distribution networks, securing regulatory approvals, and adapting its marketing strategies to local market conditions. Emerging markets with growing healthcare spending represent attractive opportunities. Timeline: 2-3 years.
- Development of New Formulations and Indications: Medexus can invest in research and development to develop new formulations of its existing products or explore new indications for those products. This can extend the product lifecycle, enhance their therapeutic value, and create new revenue opportunities. For example, exploring new indications for methotrexate could expand its market potential. Timeline: 3-5 years.
- Strategic Partnerships and Licensing Agreements: Medexus can form strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop, co-market, or distribute its products. This can provide access to new technologies, expertise, or markets, accelerating its growth and reducing its financial risk. Collaborating with larger pharmaceutical companies can enhance its credibility and market reach. Timeline: Ongoing.
What Are MEDXF's Competitive Advantages?
- Specialty pharmaceutical focus allows for targeted marketing and sales efforts.
- Established product portfolio with recognized brand names.
- Proprietary formulations and intellectual property protection.
- Strong relationships with healthcare providers in key therapeutic areas.
What Does MEDXF Do?
Medexus Pharmaceuticals Inc., formerly Pediapharm Inc., was rebranded in December 2018 to reflect its expanded focus as a specialty pharmaceutical company. Headquartered in Bolton, Canada, the company develops, acquires, and commercializes innovative medicines primarily in Canada and the United States. Medexus focuses on therapeutic areas with significant unmet needs, including oncology, hematology, rheumatology, auto-immune diseases, and allergy. Their product portfolio includes Rasuvo and Metoject, both formulations of methotrexate used to treat rheumatoid arthritis and other auto-immune conditions. IXINITY is an intravenous recombinant factor IX therapeutic used for patients with Hemophilia B. Rupall is a prescription allergy medication. Additionally, Medexus offers Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation, Trispan, a triamcinolone hexacetonide injectable suspension, and Gleolan, an optical imaging agent for patients with glioma symptoms. The company's strategy involves both organic growth through its existing product lines and strategic acquisitions to expand its portfolio and geographic reach. Medexus aims to provide specialized treatments to improve patient outcomes in its chosen therapeutic areas.
What Products and Services Does MEDXF Offer?
- Develops and commercializes specialty pharmaceutical products.
- Focuses on therapeutic areas including oncology, hematology, rheumatology, auto-immune diseases, and allergy.
- Markets Rasuvo and Metoject for rheumatoid arthritis and other auto-immune diseases.
- Offers IXINITY for patients with Hemophilia B.
- Provides Rupall, a prescription allergy medication.
- Distributes Treosulfan for allogeneic hematopoietic stem cell transplantation.
- Markets Trispan, a triamcinolone hexacetonide injectable suspension.
- Offers Gleolan, an optical imaging agent for patients with glioma symptoms.
How Does MEDXF Make Money?
- Develops or acquires rights to specialty pharmaceutical products.
- Markets and sells these products directly to healthcare providers and patients.
- Generates revenue through product sales in Canada and the United States.
- Focuses on niche therapeutic areas with unmet medical needs.
What Industry Does MEDXF Operate In?
Medexus Pharmaceuticals Inc. operates within the specialty pharmaceutical industry, a segment characterized by high research and development costs, stringent regulatory requirements, and intense competition. The industry is driven by innovation and the development of novel therapies for unmet medical needs. Medexus competes with both large pharmaceutical companies and smaller, specialized players. The market is influenced by factors such as patent expirations, pricing pressures, and healthcare reforms. Medexus's focus on niche therapeutic areas allows it to target specific patient populations and potentially achieve higher market share within those segments.
Who Are MEDXF's Key Customers?
- Hospitals and clinics
- Physicians specializing in oncology, hematology, rheumatology, and allergy
- Patients with rheumatoid arthritis, hemophilia B, allergies, and certain cancers
- Pharmacies
Company Profile
Medexus Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Kenneth d'Entremont. MEDXF has traded publicly since 2017.
Medexus Pharmaceuticals Inc. Financial Trajectory
Medexus Pharmaceuticals Inc. (MEDXF) reported $27.9M in revenue for Q2 2026, reflecting 13.0% growth compared to the prior quarter. The company recorded net income of $530K, with diluted EPS of $0.02. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MEDXF averaged $-0.02 in diluted EPS.
How Medexus Pharmaceuticals Inc. Is Valued
Medexus Pharmaceuticals Inc. carries a market capitalization of $114M, placing it in the micro-cap category. Relative to its peer group, MEDXF's quantitative score of 47/100 is roughly in line with the peer average of 54/100.
Key Financial Metrics
Return on equity for Medexus Pharmaceuticals Inc. stands at -4.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Medexus Pharmaceuticals Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.32 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Medexus Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 29.0% below estimates on average.
Forward Outlook
Wall Street analysts project Medexus Pharmaceuticals Inc. revenue of about $100.3M for fiscal 2026, with EPS near $0.00. The estimate reflects 6 contributing analysts.
MEDXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Medexus seems to be gaining traction within the social trading community. More people are talking about it positively, which can lead to increased visibility and demand.
- Recent insider activity suggests confidence in the company's future. Insiders buying shares often signals they believe the stock is undervalued.
- The overall market perception of Medexus appears to be improving. There's a growing sense that the company is undervalued and has potential for growth.
- The community is highlighting potential catalysts for Medexus, such as upcoming product launches or positive clinical trial results. This anticipation could drive the stock higher.
Bear Case
- Despite the positive sentiment, some community members remain skeptical about Medexus's long-term prospects. They cite concerns about competition and market saturation.
- There's a perception that Medexus is heavily reliant on a few key products. This lack of diversification could make the company vulnerable to market shifts.
- Some traders are worried about potential regulatory hurdles or changes in healthcare policies that could negatively impact Medexus's business.
- While insider buying is positive, there's also been some insider selling reported recently, which raises questions about their long-term conviction.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $28M | $530,185 | $0.02 |
| Q1 2026 | $25M | -$3M | -$0.08 |
| Q4 2025 | $25M | $80,000 | $0.0025 |
| Q3 2025 | $25M | -$315,000 | -$0.01 |
Based on FMP financials and quantitative analysis
MEDXF Latest News
No recent news available for MEDXF.
MEDXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEDXF.
Price Targets
Wall Street price target analysis for MEDXF.
MEDXF MoonshotScore
What does this score mean?
The MoonshotScore rates MEDXF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kenneth d'Entremont
CEO
Kenneth d'Entremont serves as the CEO of Medexus Pharmaceuticals Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on specialty pharmaceuticals and commercialization strategies. He has held various leadership positions in sales, marketing, and business development, contributing to the growth and success of several pharmaceutical companies. His expertise lies in identifying and developing niche market opportunities and building strong relationships with healthcare providers.
Track Record: Under Kenneth d'Entremont's leadership, Medexus Pharmaceuticals Inc. has focused on expanding its product portfolio and geographic reach. Key milestones include the acquisition of new products and the expansion of its sales and marketing efforts in Canada and the United States. He has overseen the company's efforts to secure regulatory approvals and reimbursement policies for its products. The company manages 82 employees under his leadership.
MEDXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Medexus Pharmaceuticals Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, lower trading volume, and less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information, price volatility, and illiquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established business operations in Canada and the United States.
- Focus on specialty pharmaceutical products with regulatory approvals.
- Experienced management team with industry expertise.
- Presence of key products like Rasuvo and IXINITY in the market.
- History as a publicly traded company, formerly Pediapharm Inc.
Common Questions About MEDXF (Healthcare)
What does the AI Score mean for MEDXF?
MEDXF holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on oncology, hematology, rheumatology, auto-immune diseases, and allergy. Their portfolio includes products like Rasuvo …
What does Medexus Pharmaceuticals Inc. do?
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company that develops, acquires, and commercializes innovative medicines focused on niche therapeutic areas, including oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's product portfolio includes Rasuvo and Metoject for rheumatoid arthritis, IXINITY for Hemophilia B, Rupall for allergies, and other specialized treatments. Medexus operates primarily in Canada and the United States, targeting unmet medical needs with specialized therapies.
What are the main risks for MEDXF?
Medexus Pharmaceuticals Inc. faces several risks, including competition from larger pharmaceutical companies, pricing pressures and healthcare reforms, patent expirations and generic competition, regulatory risks and delays in product approvals, and limited financial resources and profitability concerns. As an OTC-listed company, MEDXF also faces risks associated with lower liquidity, limited disclosure, and potential price volatility. Investors should carefully assess these risks before investing in MEDXF.
What are the key factors to evaluate for MEDXF?
Medexus Pharmaceuticals Inc. (MEDXF) holds an AI score of 47/100 (low). presents a mixed investment case. The company's focus on specialty pharmaceuticals in niche therapeutic areas like rheumatology and hematology offers potential for targeted growth. Not financial advice.
How frequently does MEDXF data refresh on this page?
MEDXF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MEDXF's recent stock price performance?
Medexus Pharmaceuticals Inc. (MEDXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio targeting niche therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MEDXF overvalued or undervalued right now?
Medexus Pharmaceuticals Inc. (MEDXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MEDXF before investing?
Before investing in Medexus Pharmaceuticals Inc. (MEDXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MEDXF to a portfolio?
Key strength of Medexus Pharmaceuticals Inc. (MEDXF): Specialized product portfolio targeting niche therapeutic areas. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending, limiting comprehensive insights.